Lantheus Holdings, Inc. (LNTH)
| Market Cap | 6.75B +36.4% |
| Revenue (ttm) | 1.55B +0.6% |
| Net Income | 279.03M +9.7% |
| EPS | 4.16 +17.8% |
| Shares Out | 65.11M |
| PE Ratio | 24.93 |
| Forward PE | 19.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 634,891 |
| Open | 103.59 |
| Previous Close | 104.61 |
| Day's Range | 100.64 - 104.70 |
| 52-Week Range | 47.25 - 111.86 |
| Beta | -0.06 |
| Analysts | Strong Buy |
| Price Target | 112.33 (+8.29%) |
| Earnings Date | Aug 6, 2026 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o... [Read more]
Financial Performance
In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price target is $112.33, which is an increase of 8.29% from the latest price.
News
Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, Au...
Lantheus price target raised to $125 from $115 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Lantheus (LNTH) to $125 from $115 and keeps a Buy rating on the shares as part of a broader research…
RadioMedix Appoints Brian A. Markison to Board of Directors
Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadershi...
Lantheus price target raised to $120 from $115 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Lantheus (LNTH) to $120 from $115 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Lantheus price target raised to $129 from $97 at B. Riley
B. Riley raised the firm’s price target on Lantheus (LNTH) to $129 from $97 and keeps a Buy rating on the shares. Following TruVu’s approval, Lantheus is positioned to compete…
US FDA declines to approve Lantheus' tumor imaging kit
The U.S. Food and Drug Administration declined to approve Lantheus Holdings' diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related conditions at a third...
Lantheus receives Complete Response Letter from FDA for LNTH-2501
Lantheus (LNTH) announced that the U.S. FDA has issued a Complete Response Letter regarding its New Drug Application for LNTH-2501, a PET diagnostic imaging kit targeting somatostatin receptor-positiv...
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to ...
Lantheus Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Expansion of PYLARIFY and Neuraceq is underway, with TruVu launching regionally by year-end and nationwide in Q1 2025. Market growth is driven by increased prostate cancer imaging and new neurology agents, while manufacturing and reimbursement strategies are being optimized.
Lantheus Holdings Transcript: 46th Annual William Blair Growth Stock Conference
The discussion highlighted advances in radiopharmaceuticals, emphasizing isotope selection, supply chain resilience, and imaging infrastructure investments. New product launches like PYLARIFY TruVu aim to improve distribution and reimbursement, supporting growing PET imaging demand.
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...
Lantheus price target raised to $115 from $100 at Mizuho
Mizuho raised the firm’s price target on Lantheus (LNTH) to $115 from $100 and keeps an Outperform rating on the shares after Bloomberg reported the company is considering a sale…
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians F...
Lantheus weighs potential $7 billion sale, Bloomberg News reports
Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that could value it at about $7 billion, Bloomberg News reported on F...
Lantheus weighs sale after Curium takeover offer, Bloomberg says
15:55 EDT Lantheus (LNTH) weighs sale after Curium takeover offer, Bloomberg says
Lantheus jumps after Bloomberg says company weighing possible sale
Lantheus (LNTH) is weighing a sale after receiving a takeover offer from Curium that values the radiopharma company at about $7B, people familiar with the matter told Bloomberg’s Michelle Davis.
Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...
Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...
Lantheus price target raised to $115 from $98 at Truist
Truist raised the firm’s price target on Lantheus (LNTH) to $115 from $98 and keeps a Buy rating on the shares. Pylarify delivered its 3rd consecutive beat at $241M and…
Lantheus price target raised to $100 from $95 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Lantheus (LNTH) to $100 from $95 and keeps an Outperform rating on the shares.
Lantheus price target raised to $115 from $85 at Citizens
Citizens analyst David Turkaly raised the firm’s price target on Lantheus (LNTH) to $115 from $85 and keeps an Outperform rating on the shares. The company delivered another strong quarter…
Lantheus price target raised to $94 from $82 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm’s price target on Lantheus (LNTH) to $94 from $82 and keeps a Neutral rating on the shares after its Q1 earnings beat.
Lantheus Holdings Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong results with revenue growth in Neuraceq® and DEFINITY®, while PYLARIFY maintained market leadership despite a year-over-year revenue decline. Regulatory milestones were achieved, and full-year guidance was reaffirmed, with growth acceleration expected in 2027.
Lantheus Holdings Earnings release: Q1 2026
Lantheus Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.